The Cannabis Company That Won't Mix Work With Pleasure
A limited supply of cannabis in the U.S. means those resources have to be divvied up carefully.
For Cronos Group, that means keeping its medical and recreational marijuana operations in completely different verticals, CEO Michael Gorenstein told Cheddar. That ensures patients’ needs are prioritized over those of recreational users.
“If you think about building a town, and you have a limited amount of building supplies, we want to make sure that we’re building a hospital before we’re building the bar,” he said.
Canada-based Cronos Group started trading on the NASDAQ on Tuesday, making it the first marijuana company to list on a major U.S. market.
“It’s a big milestone not just for us but for the entire industry,” said Gorenstein. “[It] just continues to show the acceptance that the cannabis industry is getting.”
And the industry does seem to be growing at break-neck speed. Arcview, a leading researcher of the cannabis market, stated in a [recent report](https://arcviewgroup.com/product/5th-edition/) that the industry brought in $9.7 billion in sales in 2017, and that number could grow to over $25 billion by 2021.
For the full interview, [click here](https://cheddar.com/videos/inside-the-first-cannabis-company-to-list-on-nasdaq).
Rich Hill of Principal Asset Management breaks down where real estate capital is flowing, what’s driving returns, and how 2026 could reshape the market.
From surprise celebrity overload to fewer influencers, USA Today's Ralphie Aversa breaks down the biggest Super Bowl 60 ads and why AI quietly stole the show.
Carl Lukach, CFO of Bob’s Discount Furniture, shares insights on the company’s IPO, growth strategy, and what it means for the future of the furniture market.
